ODT - Odonate Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
28.29
+2.34 (+9.02%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close25.95
Open25.81
Bid9.44 x 1300
Ask28.00 x 900
Day's Range25.12 - 28.90
52 Week Range16.50 - 43.75
Volume46,765
Avg. Volume89,887
Market Cap907.065M
Beta (5Y Monthly)1.51
PE Ratio (TTM)N/A
EPS (TTM)-4.05
Earnings DateApr 19, 2020 - Apr 23, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est38.67
  • Odonate Therapeutics Sees Hammer Chart Pattern: Time to Buy?
    Zacks

    Odonate Therapeutics Sees Hammer Chart Pattern: Time to Buy?

    Odonate Therapeutics has been struggling lately, but the selling pressure may be coming to an end soon.

  • Business Wire

    Odonate Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2019

    Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced financial results for the three and twelve months ended December 31, 2019.

  • We're Not Very Worried About Odonate Therapeutics's (NASDAQ:ODT) Cash Burn Rate
    Simply Wall St.

    We're Not Very Worried About Odonate Therapeutics's (NASDAQ:ODT) Cash Burn Rate

    Just because a business does not make any money, does not mean that the stock will go down. Indeed, Odonate...

  • Hedge Funds Have Never Been This Bullish On Odonate Therapeutics, Inc. (ODT)
    Insider Monkey

    Hedge Funds Have Never Been This Bullish On Odonate Therapeutics, Inc. (ODT)

    Is Odonate Therapeutics, Inc. (NASDAQ:ODT) a good stock to buy right now? We at Insider Monkey like to examine what billionaires and hedge funds think of a company before spending days of research on it. Given their 2 and 20 payment structure, hedge funds have more incentives and resources than the average investor. The funds […]

  • Goldman Sachs: The Good, the Bad and the Ugly of the Biotech Sector
    TipRanks

    Goldman Sachs: The Good, the Bad and the Ugly of the Biotech Sector

    Biotechs represent some of the most difficult to gauge investment opportunities on the Street. This is because shares can make big moves in either direction given a single catalyst, making these stocks more volatile in nature. Having said that, more risk-tolerant investors are constantly being drawn to biotechs as the rewards can be staggering.With investor focus locked in on the space, Goldman Sachs took a closer look at the industry as a whole, writing in a recent note to clients that the landscape is improving.“With healthcare policy and the macro backdrop becoming less of a headwind to the group relative to the concerns that pressured the XBI in late 3Q19, we see fundamentals and stock picking returning to the forefront, supported in part by a recent uptick in M&A activity,” Goldman Sachs' Paul Choi stated.Against this backdrop, Choi reminds investors that not all biotech stocks are bound for greatness. Specifically, he points to 3 names with very different growth prospects, starting coverage on one as a Buy, one as a Hold and the other as a Sell.Bearing this in mind, we used TipRanks.com to get the full scoop on the good, the bad and the ugly of the biotech industry. Here’s what we found out.Kiniksa Pharmaceuticals (KNSA)Kiniksa Pharmaceuticals, which just scored an upgrade from Goldman Sachs, wants to meet the large unmet need of patients suffering from autoinflammatory and autoimmune diseases. While shares have fallen year-to-date, Choi argues that the risk/reward profile looks promising ahead of key upcoming catalysts, possibly leading to a reappraisal.Choi highlights its pipeline as a point of strength given the significant unmet need of patients with recurrent pericarditis (RP), giant cell arteritis (GCA) and prurigo nodularis (PN).“While we believe that investors are waiting for clinical de-risking of KNSA’s assets, we recommend positioning in advance of these 2020 events as we anticipate that more value will be assigned to the pipeline upon the data read outs, as we are optimistic regarding KNSA’s sole focus on indications with limited treatment options and comparatively low competitive intensity,” the analyst explained.To top it off, the company is slated to release pivotal Phase 3 data for rilonacept, its most advanced asset, in the second half of 2020. Choi notes that as it received approval for CAPS (cryopyrin-associated periodic syndromes) treatment and the prior Phase 2 data was favorable, “we think investors already view the Phase 3 data and potential approval optimistically and do not view the data as a large inflection point for the stock.”He does however cite KNSA’s mavrilimumab drug for the treatment of giant cell arteritis, an inflammatory disease of blood vessels, as a possible big growth driver given the larger addressable market and commercial opportunity, modelled at about $1.6 billion peak sales opportunity.Based on all that KNSA has going for it, Choi assumed coverage by bumping up the rating from Hold to Buy and attaching an $18 price target. This conveys his confidence in the biotech’s ability to climb 58% higher in the next twelve months.It has been pretty quiet on Wall Street when it comes to other analyst activity. As Choi is the only analyst that has published a recommendation in the last three months, KNSA has a Moderate Buy consensus. (See Kiniksa stock analysis on TipRanks)Magenta Therapeutics (MGTA)Magenta, which uses stem cell biology to develop cures for autoimmune diseases, blood cancers and genetic diseases, is definitely promising thanks to its focus on the curative potential of stem cell transplants as well as on the different stages in the transplant process.Additionally, Magenta stands to add value if it can increase the number of patients that are initially eligible for transplants as it would expand the opportunity long-term. Choi believes that the biotech could achieve this with its earliest stage conditioning program given the amount of addressable patients. These assets include C100 and C300, antibody-drug conjugates (ADCs) for transplant conditioning, or the second step in the stem cell transplant process.“Conditioning toxicity is responsible for up to 10% of mortality following allogeneic transplants and limits the number of patients with successful transplants, and even the number of patients initially eligible for transplant. With a targeted conditioning agent, MGTA hopes to only deplete the cell types required for a successful transplant,” Choi explained. As such, the analyst expects that early data for these programs will attract substantial investor attention.However, Choi points out that its assets are mostly in the early stages and require further clinical validation. “In the near-term we think the early stages of its assets may limit share outperformance, especially without more visibility on the commercial potential in these populations,” he wrote.To this end, Choi took over coverage by issuing a Hold rating and setting an $18 price target. At this target, the potential twelve-month gain comes in at 41%.The rest of the Street’s take is more of a mixed bag. With 2 Buys and 1 Hold, the verdict is that MGTA is a Moderate Buy. However, the average price target of $19 puts the upside potential above Choi’s forecast at 49%. (See Magenta stock analysis on TipRanks)Odonate Therapeutics (ODT)The cancer drug maker represents the “the ugly” of the biotech sector according to Choi.That’s not to say that the Goldman Sachs analyst doesn’t see any positives for Odonate Therapeutics. The company has gained 114% since the start of the year, with Choi adding that its tesetaxel drug in HR+/HER2- metastatic breast cancer appears poised for approval.However, the headwinds facing ODT can’t be ignored. “The HR+/HER2- breast cancer market is competitive with many generic taxane and other chemotherapies currently available, which will likely limit commercial adoption, in our view,” Choi stated.On top of this, he predicts that utilization will primarily be in the patient population evaluated in ODT’s Phase 3 CONTESSA study. This lends itself to Choi’s prediction of sales that are about 60% below consensus estimates, on average, for the first three years following the launch. As a result, the analyst remains bearish.“Given the significant share price appreciation year-to-date, we see the valuation as stretched and look for a more attractive entry point,” Choi concluded.Taking all of this into consideration, Choi initiated his coverage of the biotech with a Sell rating. Given the $26 price target, the four-star analyst sees 14% downside in store.What do other analysts think? Looking at the consensus breakdown, it’s an even split. As 1 Buy and 1 Sell have been received in the last three months, the word on the Street is that ODT is a Hold. In addition, the $26 average stock-price forecast indicates upside potential that’s right in line with Choi’s forecast. (See Odonate stock analysis on TipRanks)

  • Does Odonate Therapeutics, Inc. (NASDAQ:ODT) Have A High Beta?
    Simply Wall St.

    Does Odonate Therapeutics, Inc. (NASDAQ:ODT) Have A High Beta?

    If you're interested in Odonate Therapeutics, Inc. (NASDAQ:ODT), then you might want to consider its beta (a measure...

  • Odonate Therapeutics Enters Oversold Territory
    Zacks

    Odonate Therapeutics Enters Oversold Territory

    Odonate Therapeutics, Inc. (ODT) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

  • 4 of the Best Stocks With Solid Earnings Acceleration
    Zacks

    4 of the Best Stocks With Solid Earnings Acceleration

    Studies have shown that a majority of successful stocks see acceleration in earnings before an uptick in the stock price.

  • Here's Why Odonate Therapeutics Stock Jumped 70.7% in June
    Motley Fool

    Here's Why Odonate Therapeutics Stock Jumped 70.7% in June

    Purchases disclosed by a company insider boosted investor confidence and the company's chemotherapy pill.

  • GuruFocus.com

    Weekly CEO Buys Highlight

    Details the CEO buys this past week for the following companies: Odonate Therapeutics, Carnival PLC, TG Therapeutics, Liberty Latin America and Biohaven

  • GuruFocus.com

    Odonate Therapeutics Inc (ODT) CEO Kevin C Tang Bought $20 million of Shares

    CEO of Odonate Therapeutics Inc (NASDAQ:ODT) Kevin C Tang bought 769,231 shares of ODT on 06/26/2019 at an average price of $26 a share.

  • GuruFocus.com

    Odonate Therapeutics Inc (ODT) CEO Kevin C Tang Bought $1.3 million of Shares

    CEO of Odonate Therapeutics Inc (NASDAQ:ODT) Kevin C Tang bought 50,000 shares of ODT on 06/18/2019 at an average price of $26.15 a share.

  • GuruFocus.com

    Odonate Therapeutics Inc (ODT) CEO Kevin C Tang Bought $2.1 million of Shares

    CEO of Odonate Therapeutics Inc (NASDAQ:ODT) Kevin C Tang bought 76,308 shares of ODT on 06/07/2019 at an average price of $27.36 a share.

  • Jazz Pharma (JAZZ) Q1 Earnings and Sales Beat Estimates
    Zacks

    Jazz Pharma (JAZZ) Q1 Earnings and Sales Beat Estimates

    Jazz Pharmaceuticals (JAZZ) reports encouraging first-quarter 2019 earnings and revenues and maintains its guidance for 2019.